160 related articles for article (PubMed ID: 12082638)
1. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
[TBL] [Abstract][Full Text] [Related]
2. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
Hemmeryckx B; van Wijk A; Reichert A; Kaartinen V; de Jong R; Pattengale PK; Gonzalez-Gomez I; Groffen J; Heisterkamp N
Cancer Res; 2001 Feb; 61(4):1398-405. PubMed ID: 11245441
[TBL] [Abstract][Full Text] [Related]
3. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
Cho YJ; Hemmeryckx B; Groffen J; Heisterkamp N
Biochem Biophys Res Commun; 2005 Aug; 333(4):1276-83. PubMed ID: 15982636
[TBL] [Abstract][Full Text] [Related]
4. Physiological signals and oncogenesis mediated through Crk family adapter proteins.
Feller SM; Posern G; Voss J; Kardinal C; Sakkab D; Zheng J; Knudsen BS
J Cell Physiol; 1998 Dec; 177(4):535-52. PubMed ID: 10092207
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphorylation of murine Crkl.
de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
[TBL] [Abstract][Full Text] [Related]
6. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
7. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
[TBL] [Abstract][Full Text] [Related]
9. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
Tari AM; Arlinghaus R; Lopez-Berestein G
Biochem Biophys Res Commun; 1997 Jun; 235(2):383-8. PubMed ID: 9199202
[TBL] [Abstract][Full Text] [Related]
11. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
[TBL] [Abstract][Full Text] [Related]
12. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
Yi SJ; Lee HT; Groffen J; Heisterkamp N
Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
[TBL] [Abstract][Full Text] [Related]
13. Acute leukaemia in bcr/abl transgenic mice.
Heisterkamp N; Jenster G; ten Hoeve J; Zovich D; Pattengale PK; Groffen J
Nature; 1990 Mar; 344(6263):251-3. PubMed ID: 2179728
[TBL] [Abstract][Full Text] [Related]
14. Bcr/Abl associated leukemogenesis in bcr null mutant mice.
Voncken JW; Kaartinen V; Groffen J; Heisterkamp N
Oncogene; 1998 Apr; 16(15):2029-32. PubMed ID: 9591787
[TBL] [Abstract][Full Text] [Related]
15. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
16. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
de Jong R; van Wijk A; Heisterkamp N; Groffen J
Oncogene; 1998 Nov; 17(21):2805-10. PubMed ID: 9840945
[TBL] [Abstract][Full Text] [Related]
17. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of transformation by the BCR-ABL oncogene.
Sattler M; Griffin JD
Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
[TBL] [Abstract][Full Text] [Related]
20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]